Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Overall results from a multicenter study involving more than 1000 patients with plaque psoriasis treated with tazarotene 0.1% gel plus a topical corticosteroid are soon to be published. This report considers a subgroup of 246 patients from that study who were switched from calcipotriene plus corticosteroid treatment (at baseline) to tazarotene plus corticosteroid for up to 12 weeks. Moderate (> or = 50%) global improvement was achieved in 75% of patients between the baseline visit (when on calcipotriene therapy) and the final visit (when on tazarotene therapy). Considerable additional reductions (38%-50%) in overall severity of plaque psoriasis, plaque elevation, scaling, pruritus, and overall discomfort were achieved over and above improvements already achieved with calcipotriene therapy. Furthermore, 74% of patients were satisfied with their treatment regimen at the final visit (when on tazarotene therapy), compared with 17% at baseline (when on calcipotriene therapy).